Skip to content
DataLookout
Menu

BiPASSNCT07052214

PSMA PET Combined With MRI for the Detection of PCa

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words
    • Enrollment closed, study ongoing
    • Site details revised at 18 of 18 sites
  2. Notable Primary completion pushed from Jun 2026 to Jan 2027v3 Show 5 more changesShow less
    • Enrollment increased: 204 → 338 participants
    • Eligibility criteria shortened, about 143 words
    • Trial sites expanded: 1 → 18 locations
    • Study completion pushed from Nov 2026 to Apr 2027
    • Study description expanded, about 6 words
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2025 to Aug 18, 2025
    • Collaborators expanded, about 3 words
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Primary Objective
Timeframe: 12 months
Co-Primary Endpoint
Timeframe: 12 months

Arms and interventions

Illuccix: 68Ga-PSMA-11/Gallium Ga 68 GozetotideOther

This is a single arm study. All participants will first undergo mpMRI and PSMA PET scans (one single IV bolus of Gallium Ga 68 Gozetotide administered)

Drugs: 68Ga-PSMA-11

Sites

18 sites in 2 countries

United States 16, Australia 2